BANGI: Biogenes Technologies Sdn Bhd (Biogenes), a Malaysian-based company in the field of molecular diagnostics and genomics has signed a licensing agreement with Infrastructure University Kuala Lumpur (IUKL) to commercialise Aptamer technology.
Aptamer, a synthetic alternative to antibodies acts as molecular probes to detect and measure desired target molecules in a sample. This innovation is revolutionary and it may change the way the human body is monitored for clinical purposes as well as to check for
